Hyponatremia
3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasConivaptan
Biogenlixivaptan
AstellasYM087
Bausch HealthPEG-SD
Clinical Trials (4)
Total enrollment: 736 patients across 4 trials
Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients
Start: May 2008Est. completion: Jun 20100
Phase 3Withdrawn
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
Start: Jan 2007652 patients
Phase 3Completed
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
Start: Aug 2000Est. completion: Feb 200384 patients
Phase 3Completed
Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS
Start: Jun 2010Est. completion: Sep 2012
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space